Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company focused on engineered NK cell therapies for autoimmune diseases, has confirmed its participation in two prominent investor conferences scheduled for March 2026. The company will present at the TD Cowen 46th Annual Health Care Conference on March 2 in Boston, followed by an appearance at the Leerink Global Healthcare Conference on March 10 in Miami.
Both conference presentations will be made available to investors through live webcast, allowing broader access to Nkarta's corporate updates and research developments. The dual conference participation reflects the company's commitment to engaging with the institutional investment community and providing updates on its pipeline progress.
Nkarta's clinical-stage approach to developing engineered NK cell therapies represents an emerging therapeutic category within the immunotherapy landscape. The March conference schedule provides investors an opportunity to assess the company's clinical and operational developments during a period of continued advancement in cell-based immunotherapy approaches.